Evidence map›Paper›PMID 16026361›Full record

Trial reportDiabetic medicine : a journal of the British Diabetic Association2005

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.

T Yamanouchi, T Sakai, K Igarashi, K Ichiyanagi, H Watanabe, T Kawasaki

Registry-linked trialOpen access · bronzeAbstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetic medicine : a journal of the British Diabetic Association, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04943692 (Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes), which is not on this map. Cited by 23 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04943692 phase3suspendedstarted 2021, after this paper: background citation

Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes

Ran2021Enrolled500Registered outcomes13Posted comparisons0ConditionsType 2 DiabetesArmsMetformin glycinate, Metformin hydrochloride
PMID 18784090PMID 7895460PMID 8743335PMID 11225659PMID 9742977PMID 20388897PMID 9428831PMID 17145742PMID 19307526PMID 7601013PMID 14502106PMID 7306436other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Metformin monotherapy for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020 · on this map
    Pooled it
  2. Pooled it
  3. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2010 · on this map
    Pooled it
  4. Pioglitazone for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2006 · on this map
    Pooled it
  5. Review
  6. Article
  7. Review of methods for detecting glycemic disorders.Diabetes research and clinical practice · 2020
    Review
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Pharmacogenetics of Anti-Diabetes Drugs.Pharmaceuticals (Basel, Switzerland) · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

T YamanouchiDepartment of Internal Medicine, University of Teikyo, Itabashi-ku, Tokyo, Japan. yama@med.teikyo-u.ac.jp
T Sakai
K Igarashi
K Ichiyanagi
H Watanabe
T Kawasaki
Teikyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo compare the metabolic effects of pioglitazone, metformin, and glimepiride in the treatment of Japanese patients with newly diagnosed Type 2 diabetes.

methodsA total of 114 patients with Type 2 diabetes who had never used oral hypoglycaemic drugs were studied for 12 months. Patients were randomly assigned to pioglitazone (30-45 mg/day, n = 38), metformin (750 mg/day, n = 39), or glimepiride (1.0-2.0 mg/day, n = 37). The effect of treatment on fasting plasma glucose (FPG), glycated haemoglobin (HbA(1c)), 1,5-anhydroglucitol (1,5AG), total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides, free fatty acids (FFA), and fasting plasma insulin levels was monitored monthly. Body weight and safety data were also collected.

resultsEight patients withdrew from the study (three in the pioglitazone group, two in the metformin group, and three in the glimepiride group). The rate of reduction of HbA(1c) was fastest in patients receiving glimepiride and slowest in patients receiving pioglitazone. Although there were no significant differences among the three groups in HbA(1c) levels at the end of the study, patients taking pioglitazone had relatively lower FPG and 1,5AG levels than patients taking the other two drugs. These results suggest that pioglitazone acts predominantly on nocturnal metabolism rather than at mealtimes. FFA were reduced significantly in those taking pioglitazone (542.2 microEq/l vs. 237.3 microEq/l; P < 0.01) before a decrease in HbA(1c) was apparent. The change in FFA levels correlated with the change in HbA(1c) (r = 0.409, P < 0.01). There were no significant differences in other lipid parameters among the groups.

conclusionsPioglitazone, metformin, and glimepiride are equally effective in reducing blood glucose in patients with newly diagnosed Type 2 diabetes. However, their specific characteristics, such as the rapid action on blood glucose levels of glimepiride and the favourable action on FPG and FFA of pioglitazone, should be considered when choosing an appropriate agent.

Indexed as

AgedAsian PeopleBlood GlucoseBody Mass IndexDiabetes Mellitus, Type 2Drug Therapy, CombinationFastingFemaleGlycated HemoglobinHumansHypoglycemic AgentsInsulinLipidsMaleMetforminMiddle AgedBlood GlucoseglimepirideGlycated HemoglobinHypoglycemic AgentsInsulinLipidsMetforminPioglitazoneSulfonylurea CompoundsThiazolidinediones

Identifiers

PMID16026361
OpenAlexW2104785880

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.